Ratings Cabio Biotech (Wuhan) Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
15.65 ^CNY	-2.00%		-7.83%	-12.57%

Apr. 30	Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises	RE
Apr. 26	Cabio Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 59% by 2026.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts covering this company mostly recommend stock overweighting or purchase.

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The group usually releases earnings worse than estimated.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CABIO BIOTECH (WUHAN) CO., LTD.	-12.57%	364M		-
ZHEJIANG NHU COMPANY LTD.	+13.74%	8.18B		D+
BELLRING BRANDS, INC.	+5.29%	7.53B		C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	-0.42%	5.89B		-
THE SIMPLY GOOD FOODS COMPANY	-6.67%	3.7B		B-
BYHEALTH CO., LTD	-10.75%	3.57B		D
XIAMEN KINGDOMWAY GROUP COMPANY	-8.21%	1.26B	-	-
HERBALIFE LTD.	-29.10%	1.08B		B+
SIRIO PHARMA CO., LTD.	+14.92%	991M		-
USANA HEALTH SCIENCES, INC.	-12.46%	894M		C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality